Revolution Medicines, Inc. 8-K

What Happened
Revolution Medicines, Inc. (RVMD) filed an 8-K on April 13, 2026 announcing topline results from the global, randomized, controlled Phase 3 RASolute 302 trial of daraxonrasib in previously treated metastatic pancreatic ductal adenocarcinoma (PDAC). Daraxonrasib, taken orally once daily, showed statistically significant and clinically meaningful improvements in both progression-free survival (PFS) and overall survival (OS) versus standard-of-care intravenous cytotoxic chemotherapy. In the intent-to-treat population, median OS was 13.2 months for daraxonrasib versus 6.7 months for chemotherapy (hazard ratio 0.40; p < 0.0001). The company reported daraxonrasib was generally well tolerated with a manageable safety profile and no new safety signals. Based on this first interim analysis, all PFS and OS endpoint results are considered final.

Key Details

• Trial: Phase 3 RASolute 302; global, randomized, controlled; patients with previously treated metastatic PDAC.
• Overall survival: median OS 13.2 months (daraxonrasib) vs. 6.7 months (chemotherapy); HR = 0.40; p < 0.0001.
• Administration and safety: oral once-daily daraxonrasib; manageable safety profile, no new safety signals reported.
• Next steps: Company intends to submit data to global regulators, including the FDA, as part of a future NDA under a Commissioner’s National Priority Voucher.
• Filing: Results disclosed via Form 8-K; filing includes standard forward-looking statements about development, regulatory timing, and risks.

Why It Matters
These topline Phase 3 results indicate a large improvement in survival for a difficult-to-treat cancer (previously treated metastatic PDAC), which could meaningfully change the treatment landscape if regulators accept the data and approve daraxonrasib. For investors, the announcement is material because it supports a potential regulatory submission (NDA) and could drive future revenue and valuation if approval and commercialization succeed; however, the company’s filing also notes the usual development and regulatory risks.